{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=32", "query": { "condition": "Pharmacokinetics and Pharmacodynamics", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 2339, "total_pages": 234, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T18:39:28.431Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01226316", "title": "Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancy", "Safety and Tolerability", "Pharmacokinetics", "Pharmacodynamics", "Tumour Response", "Advanced or Metastatic Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "PIK3CA", "AKT1", "PTEN", "ER Positive", "HER2 Positive" ], "interventions": [ { "name": "AZD5363", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 285, "start_date": "2010-12-01", "completion_date": "2024-12-03", "has_results": false, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 12, "location_summary": "Los Angeles, California • Stanford, California • West Hollywood, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01226316" }, { "nct_id": "NCT02783300", "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3326595", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2016-08-30", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 6, "location_summary": "Denver, Colorado • Miami, Florida • New York, New York + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783300" }, { "nct_id": "NCT07235059", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "OJR520", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 112, "start_date": "2025-11-20", "completion_date": "2028-01-21", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07235059" }, { "nct_id": "NCT06120283", "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Breast Cancer", "Metastatic Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Hormone Receptor Positive Malignant Neoplasm of Breast", "HER2-negative Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Anti-Diarrheal Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2023-12-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 9, "location_summary": "Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120283" }, { "nct_id": "NCT07610473", "title": "A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "DT-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Draig Therapeutics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 118, "start_date": "2026-05-14", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Lafayette", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07610473" }, { "nct_id": "NCT07364669", "title": "Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "Insulex® R (soluble human insulin, biosimilar)", "type": "DRUG" }, { "name": "Humulin® R (soluble human insulin, biosimilar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laboratorios Pisa S.A. de C.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2024-10-24", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07364669" }, { "nct_id": "NCT02439346", "title": "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medical Oncology" ], "interventions": [ { "name": "BAY1143269 tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-06-15", "completion_date": "2017-04-24", "has_results": false, "last_update_posted_date": "2018-03-07", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 3, "location_summary": "Dallas, Texas • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439346" }, { "nct_id": "NCT05080842", "title": "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-11-12", "completion_date": "2024-04-04", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080842" }, { "nct_id": "NCT01407380", "title": "Study of PWT33597 Mesylate in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignancies" ], "interventions": [ { "name": "PWT33597 mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pathway Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-06", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Boston, Massachusetts + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407380" }, { "nct_id": "NCT07867288", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonobstructive Hypertrophic Cardiomyopathy" ], "interventions": [ { "name": "HTX-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haya Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2026-10", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-16T18:39:28.431Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07867288" } ] }